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FGF21Methionine–choline-deﬁcient (MCD)diet is awidely used dietarymodel of non-alcoholic steatohepatitis (NASH)
in rodents. However, the contribution of adipose tissue to MCD-induced steatosis, and inﬂammation as features
of NASH are not fully understood. The goal of this study was to elucidate the role of adipose tissue fatty acid (FA)
metabolism, adipogenesis, lipolysis, inﬂammation and subsequent changes in FA proﬁles in serum and liver in
the pathogenesis of steatohepatitis. We therefore fed ob/ob mice with control or MCD diet for 5 weeks. MCD-
feeding increased adipose triglyceride lipase and hormone sensitive lipase activities in all adipose depots
which may be attributed to increased systemic FGF21 levels. The highest lipase enzyme activity was exhibited
by visceral WAT. Non-esteriﬁed fatty acid (NEFA)-18:2n6 was the predominantly elevated FA species in serum
and liver ofMCD-fed ob/obmice, while overall serum total fatty acid (TFA) compositionwas reduced. In contrast,
an overall increase of all FA species from TFA pool was found in liver, reﬂecting the combined effects of increased
FA ﬂux to liver, decreased FA oxidation and decrease in lipase activity in liver. NAFLD activity scorewas increased
in liver, while WAT showed no changes and BAT showed even reduced inﬂammation. Conclusion: This study
demonstrates a key role for adipose tissue lipases in the pathogenesis of NASH and provides a comprehensive
lipidomic proﬁling of NEFA and TFA homeostasis in serum and liver. Our ﬁndings provide novel mechanistic
insights for the role of WAT in progression of MCD-induced liver injury.
© 2014 The Authors. Published by Elsevier B.V.Open access under CC BY license.1. Introduction
Non-alcoholic fatty liver disease (NAFLD) includes a disease spec-
trum ranging from simple fatty liver (steatosis), to non-alcoholic
steatohepatitis (NASH), cirrhosis and ultimately hepatocellular
carcinoma (HCC) [1]. NAFLD is commonly observed in obese individuals,
diabetics and patients with metabolic syndrome [2].acetyl-CoA carboxylase; ACSL1, long-c
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is an intermediate in synthesis of S-adenosylmethionine (SAM) and
glutathione (GSH), two important antioxidants [9]. Therefore methi-
onine deﬁciency predisposes to oxidative stress, inﬂammation and
ﬁbrosis [8]. Additionally, gut-derived bacterial products play a causal
role in the pathogenesis of NASH [5]. MCD diet increases plasma
endotoxin levels which enhance steatohepatitis via toll-like receptor-4
signaling and inﬂammation is diminished in endotoxin resistant
MCD-fed mice [6]. Most studies on MCD-induced NASH model have
focused largely on the factors pertaining to liver while the role of
adipose tissue in the pathogenesis of NASH has not been well under-
stood. A multiple parallel hit model has been proposed for the
pathogenesis of NASH where the initial step (ﬁrst-hit) involves fat
accumulation in liver and many hits, especially gut-derived and adi-
pose tissue-derived factors, may act in parallel, resulting in hepatic
inﬂammation [10,11].
There are 3 sources of FAs for hepatic TG accumulation: (i) diet,
(ii) de novo lipogenesis (DNL) and (iii) adipose tissue [12–14].
Altered lipid composition in both plasma and liver has been shown
in patients with NAFLD and NASH and hence has been implicated
in triggering inﬂammation and serving as endogenous danger signals
[15,16]. Additionally, hepatic lipotoxicitymay ensuewhen hepatic capac-
ity to utilize (oxidation and newmembrane generation), store and export
fatty acids (FAs) in the formof VLDL is overwhelmed by FAﬂux from the
periphery or hepatic DNL [12,14]. According to this concept, pure fatty
liver can progress to NASH when adaptive mechanisms protecting
hepatocytes from FA-mediated lipotoxicity are overwhelmed [12,17].
Adipose tissue is themain source of FAs in circulation. Obesity, insu-
lin resistance, and NAFLD are all associated with increased adipose
tissue lipolysis [12,13]. Additionally, rapidweight loss (e.g. due to signif-
icant calorie restriction and bariatric surgery) induces lipolysis in the AT
[18,19]. Thus understanding the factors inﬂuencing lipolysis may be of
signiﬁcant importance. Adipocyte triglyceride lipase (ATGL) is the rate
limiting enzyme in triglyceride hydrolysis [20–22] and utilizes
triacylglycerol (TG) as a substrate. ATGL catalyzes the ﬁrst step of
TG breakdown, whereas hormone-sensitive lipase (HSL) subse-
quently hydrolyses diacylglycerol (DG) into monoacylglycerol (MG).
Finally monoacylglycerol lipase (MGL) hydrolyses monoacylglycerol
(MG) to FA and glycerol. These three enzymes constitute the canonical
pathway for triglyceride breakdown [20–23].
We previously showed that MCD feeding in non-diabetic, non-
obese, wild-type (WT) mice for 2 weeks resulted in WAT loss due to
increased lipase activity in WAT depots [3]. In the current study, we
expand our previous observation to study the role of adipose tissue in
the pathogenesis of NASH in ob/ob mouse model (with key features of
obesity and insulin resistance) under MCD challenge. Our ﬁndings
show that lipase activities were elevated in all adipose depots in line
with increased FGF21 signaling. This resulted in increased FA ﬂux
from adipose tissue to the liver, thereby causing steatosis, inﬂammation
and change in FA homeostasis in serumand liver.WhileMCD feeding had
no effect on inﬂammatory markers in WAT, in BAT it was signiﬁcantly
decreased due to increased BAT activity.2. Methods
2.1. Animal care and use
ob/ob Mice were obtained from Charles River, Germany. All animals
were housed under a 12:12-h light/dark cycle and permitted ad libitum
consumption ofwater and diet. Micewere harvested in non-fasted state
between 12 and 4 pm. All experimental protocols were approved by the
local Animal Care and Use Committees according to criteria outlined in
the Guide for the Care and Use of Laboratory Animals prepared by the U.S.
National Academy of Sciences (National Institutes of Health publication
86-23, revised 1985).2.2. Diet
MCD and its corresponding control diet was obtained from Safe-
diets (Augy, France). The diets were identical in all nutrients except
methionine (2.8 g/kg) and choline (1.6/kg), which were present in the
control diet only. Both diets provided 64.2% kcal as carbohydrate,
25.8% kcal as protein, and 10% kcal as fat.2.3. Serum analysis
Blood was collected by retro-orbital puncture under anesthesia and
centrifuged for 15 min at 4500 rpm. Serum was stored at−80 °C until
analysis. ALT, AST, bile acids and bilirubin were analyzed on a Hitachi
917 analyzer (Boehringer Mannheim, Mannheim, Germany). Serum
FFAs were determined by using commercial kit (Wako Chemicals,
Neuss, Germany) on an Olympus AU640 analyzer (Olympus Diagnostika,
Hamburg, Germany). Serum FGF21 was measured by using ELISA
kit (Millipore). Plasma glucose was measured by using Accu-Check
glucometer (Roche Diagnostics).2.4. Assay for tissue TG hydrolase activity
TG hydrolase assay was performed as previously described [3,24]. In
brief, WAT and liver samples of mice were surgically removed and
washed in phosphate-buffered saline (PBS), containing 1 mM EDTA and
5 U/ml heparin. Tissues were stored in liquid nitrogen until use.
Homogenization was performed on ice in lysis buffer (0.25 M sucrose, 1
mM EDTA, 1:2000 dilution of protease inhibitor cocktail, pH 7.0) using
MagNA Lyser (Roche). Tissue lysates were centrifuged twice at 13,000
rpm, 4 °C. The lipid free infranatant (cytosolic fraction) was collected
and used for TG hydrolase assays. The substrate for the measurement of
TG hydrolase activity containing triolein and [9,10-3H]triolein (Hartmann
analytic GMBH, Vienna, Austria) as radioactive tracerwas emulsiﬁedwith
phosphatidylcholine and phosphatidylinositol in 100 mM potassium
phosphate buffer (pH7) using a sonicator, followed by addition of 5% FA
free bovine serum albumin. Final substrate concentration was 167 nmol
of triolein/assay (8000 cpm of [9, 10-3H]triolein/nmol). 25 μg WAT, 35 μg
BAT and 50 μg of liver cytosolic fractions (0.1 ml) supplemented with or
without speciﬁc inhibitor for HSL(10 μM) (NNC 0076-0000-0079; a kind
gift from Novo Nordisk, Denmark) were incubated with 0.1 ml of the
substrate in awater bath at 37 °C for 60min. The reactionwas terminated
by adding 3.25ml of methanol/Chloroform/heptane (10:9:7) and 1ml of
0.1 M potassium carbonate, 0.1 M boric acid, (pH 10.5). After centrifuga-
tion at 2300 rpm for 15min, radioactivity in 1ml of the upper phase was
determined by liquid scintillation counting in LS 6500 Multi-Purpose
Scintillation Counter (Beckman Coulter, Fullerton, CA). ATGL activity
was deﬁned as the remaining activity not inhibited by the HSL inhibitor
(activity in the presence of the HSL inhibitor). HSL activity was calculated
by subtracting the activity obtained in the presence of the HSL inhibitor
from total activity.2.5. Western blot analysis of cytosolic ATGL and HSL
For ATGL and HSLWestern blots, cytosolic extracts were used as de-
scribed for TG hydrolase activity. Blots were probed with antibodies
speciﬁc toATGL (Cell Signaling, cat. no. 2439S; 1:1000), HSL (Cell signal-
ing, cat. no. 4107S; 1:500) and β-Actin (Sigma-Aldrich, cat. no. A5441)
as primary antibodies and a peroxidase-conjugated afﬁnity-puriﬁed
secondary antibody obtained from Cell signaling (cat. no. 7074; 1:3000)
for ATGL, and HSL and from Dako (cat. no. P0260; 1:1000) for β-Actin.
For quantiﬁcation of relative expression levels, blots were scanned by
using a densitometer (BioRad) and quantiﬁed with ImageJ software
(NIH). 20 μg and 30 μg of cytosolic extract were used for ATGL and HSL
blots for WAT and liver, respectively.
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Gonadal and BAT fat pads of ob/ob mice fed either control or MCD
diet were ﬁxed in 4% buffered formaldehyde and embedded in parafﬁn.
Hematoxylin- and eosin (H&E)-stained WAT (3 μm thick) and BAT (2
μm thick) sections were used to take random pictures (6–10) from dif-
ferent locations at 40× magniﬁcation. The area of each adipocyte was
determined by using the Cell Sens Standard 1.8.1 software by
manually outlining each cell. On an average 40 and 60 fat cells from
WAT and BAT respectively, were measured from each sample for the
control group and 70 and 120 from WAT and BAT respectively for the
MCD group.2.7. Immunohistochemistry for UCP-1 and F4/80
For detection of UCP-1 positive cells, 3 μm and 2 μm thick parafﬁn
sections of gonadal WAT and BAT respectively were mounted on
charged glass slides. Deparafﬁnization was done in xylene, rehydrated
in ethanol, treated with 1 mM sodium EDTA buffer((pH 8.0) in micro-
wave, followed by 1% hydrogen peroxide. Sections were incubated for
1 h with rabbit polyclonal UCP-1 antibody (Abcam, ab10983; 1:100
dilution in antibody diluent (DAKO)). Sections were incubated with
Dako Real real Envision Detection System (K5700) for 30 min. Subse-
quently, detection was carried out by using AEC Substrate Chromogen
ready-to-use (Dako K3464) under microscopic control. Negative con-
trols were performed in the absence of primary antibody. Nuclei were
counter-stained in Hemalaun nach Mayer for 30 s. Aquatex as glue
was used for ﬁxing the cover slips onto the slide.
For detection of F4/80 positive cells, slides were deparafﬁnized in
xylene, reyhdrated in ethanol and treated with 0.1% protease XXIV,
followed by 1% hydrogen peroxide. Sections were incubated overnight
at 4 °C with rat-anti-mouse F4/80 antibody (AbD Serotec, MCA497GA;
1:50 dilution in antibody diluent (DAKO)). Subsequently, sections
were incubated with polyclonal rabbit-anti-rat secondary antibody
(DAKO, E0468, dilution 1:100 in antibody diluent (DAKO)) for 30 min
followed by incubation with rabbit on rodent HRP-polymer (catalog
no. RMR622; Biocare Medical) for 30 min. Subsequently, detection
was carried out as stated above. For quantiﬁcation of F4/80 positive
cells, the slides were scanned at 40× magniﬁcation by using scanscope
(Aperio technologies, CA). The positive cells were then manually quan-
tiﬁed in 10, 40× power ﬁelds from each sample.2.8. GC–NICI/MS of free fatty acids
Mouse livers (50–70 mg) were homogenized in 0.5 ml of PBS and
0.5 ml of methanol. Each sample was spiked with 1.2 nmol of 15:0
fatty acid as internal standard immediately. For serum, 2.5 nmol of
15:0 was added to 50 μl of the sample followed by 0.5 ml of methanol.
Then, lipids were extracted according to Bligh and Dyer method [25].
Lipid extracts were dried and dissolved in 50 μl of a pentaﬂuoro benzyl
bromide solution (3.4% in acetonitrile) and 10 μl of N, N-diisopropyl
ethanolamine. After 10 min of incubation at room temperature
samples were evaporated under a stream of nitrogen and resuspend-
ed in 50 μl of hexane. A Trace-DSQ GC–MS (Thermo Scientiﬁc, Austin,
TX) equipped with a TR-FAME 30 m column was used in splitless
mode with 1 ml/min helium as carrier gas and 300 °C injector tem-
perature. The initial oven temperature of 150 °C was held for 1 min
and then increased to 200 °C at a rate of 25 °C/min followed by
325 °C at a rate of 12.5 °C/min and held for 2 min. The mass spec-
trometer was run in negative ion chemical ionization (NICI) mode.
Fatty acids were detected in full scan as carboxylates after loss of
the pentaﬂuoro benzyl moiety. Methane was used as CI gas. Source
temperature was set to 250 °C and the transfer line temperature to
330 °C.2.9. GC–EI/MS of total fatty acids (free and esteriﬁed)
Lipidswere extracted according to Bligh &Dyermethod as described
above. For liver, each sample was spiked with 375 nmol of 15:0 fatty
acid as internal standard. For serum, 22.5 nmol of 15:0 was added to
50 μl of the sample. Then lipidswere dried and suspended in 1mlmeth-
anol NaOH. After 10 min incubation at 80 °C, samples were cooled for
5 min on ice. Then, 1 ml BF3 was added and incubated for 10 min at
80 °C. Fatty acid methyl esters were extracted with 1 ml saturated
NaCl and 2 ml hexane. The hexane phase was dried and methyl esters
dissolved in 1.5 ml hexane. Trace-DSQ GC–MS equipped with a TR-
FAME 30 m column was used for analysis. Helium was used as carrier
gas at a ﬂow of 1.3 ml/min, in split mode, at 250 °C injector tempera-
ture. Initial oven temperature of 150 °C was held for 0.5 min and then
temperature was increased to 180 °C at a rate of 10 °C/min. This was
followed by a further increase to 190 °C at a rate of 0.5 °C/min and
then increased to 250 °C at a rate of 40 °C/min and kept for 3 min. The
mass spectrometer was run in electron impact mode and fatty acids
were detected in full scan of m/z 80–400. Source temperature was set
to 250 °C and the transfer line temperature to 200 °C.
2.10. Hepatic TG determination
50–70mg of liver samples was homogenized inmethanol inMagNA
Lyser (Roche). Lipids were extracted with chloroform/methanol/glacial
acetic acid (66/33/1 v/v/v) and phase separation was achieved by
addition of water. The lower organic phase was evaporated and
reconstituted by brief sonication in 0.1% Triton X-100. For protein
measurement, the tissue homogenates were solubilized in 0,3N
NAOH/0.1% (w/v) sodium dodecylsulfate at 65 °C for several hours
and the protein content was determined by using Bio-Rad Protein
Assay (Lowry). TG content was measured with a commercial kit from
Diagnostic Systems International (Holzheim, Germany).
2.11. RNA isolation and qRT-PCR analysis was performed as previously
described [3]
mRNA levels were normalized to 36b4 as housekeeping gene.
Sequences of primers used for qRT-PCR are available upon request.
mRNA levels of inﬂammatory markers in WAT was analyzed from go-
nadal, perirenal and subcutaneous depots and only the gonadal WAT
is shown (representative). Analysis of mRNA expression of other
genes (except inﬂammatory markers) was performed from the stated
depot.
2.12. Histology scoring
The liver tissues were ﬁxed in 10% neutral buffered formalin and
embedded in parafﬁn. 2 μm thick liver sections were stained with
H&E or sirius red. Histological examination was performed in a
blinded fashion by an experienced gastrointestinal board certiﬁed
pathologist (Prof. Dr. Carolin Lackner) using the widely accepted
Nonalcoholic Steatohepatitis Clinical Research Network (CRN) histo-
logical scoring system for NAFLD as described [26]. Brieﬂy, steatosis
and inﬂammation scores ranged from 0 to 3with 0 beingwithin normal
limits and 3 beingmost severe. Individual scoreswere assigned for each
parameter. The NAFLD activity score (NAS) was calculated from the
sum of the individual scores for steatosis, inﬂammation and ballooning.
The latter change was not observed and therefore scored as zero.
2.13. Statistics
Data are presented as mean ± SD of the reported animals in each
group (4–6 animals). Statistical analysis was performed by using
SPSS V.14.0. Statistical signiﬁcance was determined by Student's
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for p b 0.05 (*, #, §), p b 0.01(**, ##, §§), and p b 0.001 (***, ###, §§§).
3. Results
3.1. Effect of MCD diet on adipose depots and serum non-esteriﬁed fatty
acid (NEFA) levels
To delineate the role of adipose tissue in steatohepatitis in a mouse
model which combines key features of obesity and insulin resistance,
we challenged ob/ob mice with MCD diet for 5 weeks to promote pro-
gression of steatosis to NASH. MCD-fed ob/ob mice lost 38% of their
bodyweight at the end of 5 weeks (Fig. 1A) due to substantial reduction
of all adipose depots: gonadal (−48%), perirenal (−44%), visceral
(−53%) and BAT (−60%) (Fig. 1B) in line with the previous ﬁndings
in MCD-fed db/db mice [27]. The expression of transcription factors
known to promote adipogenesis, including, PPARγ2, C/EBPα, ap2/
FABP4 and SREBP1c was similar in both control and MCD-fed mice
(Fig. 1C) suggesting that defective adipogenesis was not responsible
for WAT loss. Additionally, expression of genes involved in (i) FA
synthesis, including ACC1, SCD1, ACSL1; (ii) FA storage, including
DGAT1, DGAT2, LIPIN1 and (iii) FA catabolism, including PPARα and
CPT1β were similar in both the groups which suggest that these pro-
cesses of FA metabolism were not responsible for WAT loss in MCD-
fed mice (Fig. 1C). Since choline deﬁciency may affect the phosholipid
synthesis and thereby membrane structure and cellular function of the
adipocyte, we analyzed genes involved in phosphotidylcholine (PC)
and phosphotidylethanolamine (PE) synthesis. PCYT1A, involved in
synthesis of PC from diacylglycerol was marginally increased (18%) in
MCD-fed ob/ob mice (Fig. 1D, left). However, the ethanolamine-
phosphate PCYT2 gene, involved in synthesis of PE from diacylglycerol
was decreased by 30% (Fig. 1D, middle). Additionally, mRNA expression
of PEMT, that catalyzes conversion of PE to PC,wasmarginally increased
(27%) (Fig. 1D, right). Taken together, these data suggest a moderatePe
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Fig. 1. Effect ofMCDdiet on adipose tissuemass, itsmolecularmarkers and lipolysis. ob/obMice
harvested in non-fasted state. (A) Final body weight. (B) Fat depot analysis of gonadal, perirena
synthesis, storage and catabolism in gonadalWAT. (D)mRNA expression of genes involved in p
concentration normalized to the total WAT weight. n = 6 per group. Bars represent mean + Sshift towards an increase in de novo PC synthesis from diacylglycerol
and PE. Despite substantial WAT loss, serum NEFA concentrations
were not elevated (Fig. 1E). This apparent discrepancy may be attribut-
ed to the reduced amount of WAT in the MCD-fed group since NEFA
levels were 1.5-fold elevated when normalized to the WAT weight
(Fig. 1F).
3.2. Increased peripheral lipolysis inMCD-fed ob/obmice is due to increased
ATGL and HSL activity in adipose depots
Loss of adipose depots and increased ratio of plasma free FAs per
gram fat mass indicated an elevated lipolytic rate under non-fasting
state. Indeed, as shown in (Fig. 2A–E, white bars), total TG hydrolase
activity increased in all adipose depots with the highest increase
observed in visceral (+130%), followed by perirenal (+83%), subcuta-
neous (+82%), gonadal WAT (+63%) and BAT (+86%). The maximal
increase of ATGL activity (HSL-inhibited TG hydrolase activity) was
seen in visceral (+204%), followed by subcutaneous WAT (+112%),
BAT (+93%), perirenal (+82%) and gonadal WAT (+78%) (Fig. 2A–E,
black bars). Compared to ATGL, HSL activity (determined by subtraction
of HSL inhibited lipase activity from total lipase activity) was induced to
a lesser extent by 108% in visceral, 71% in subcutaneous, 84% in BAT, 85%
in perirenal and 65% in gonadal WAT (Fig. 2A–E, gray bars). In line,
Western blot analysis also showed increased ATGL and to a lesser extent
HSL protein expression in MCD-fed ob/ob mice (Fig. 2F). Collectively,
these data show that MCD induces ATGL and HSL activities, resulting
in loss of WAT and BAT depots in MCD-fed ob/ob mice. The physiologi-
cal effect of enhanced lipolysis on morphology of adipose tissue was
investigated by determining the adipocyte size from gonadal WAT and
BAT. The fat cell size was very heterogeneous in all the areas, however
the cell size decreased by−35% and−43% inWAT and BAT respectively
in response to MCD feeding (Fig. 2G). Additionally, unlike the multi-
locular morphology of BAT, in ob/ob mice the BAT was unilocular in
both the groups (Fig. 2G, right), as also shown previously [28].0
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enhanced FGF21 levels
FGF21 is an endocrine hormone that plays a central role in energy
homeostasis, substrate metabolism and fasting in rodents. Its admin-
istration reduces adiposity in mice [29–31]. Importantly, it induces
lipolysis in adipose tissue via elevating ATGL and HSLmRNA and pro-
tein expression [31,32]. We therefore, hypothesized that increased
lipase activity in MCD-fed ob/ob mice may be due to increased
FGF21 signaling. Subsequently, we analyzed the systemic effect of
FGF21 on WAT and BAT depots. With disease progression, MCD-fed
ob/ob mice were no longer hyperphagic as also previously shown
in db/db mice [27] (Fig. 3A). This may mimic a fasting-like response
in these mice. In line, we observed an increase in FGF21 mRNA ex-
pression in liver (Fig. 3B). Importantly, serum FGf21 levels were in-
creased by 60% in MCD-fed ob/ob mice (Fig. 3C). In line, with the
well-established effect of FGF21 on subcutaneous (sc) WAT and
BAT [29], the mRNA expression of FGF21 receptors- FGFR1 and
βKlotho were increased by +117% and +208% respectively in sc.
WAT (Fig. 3D). In BAT, the expression of FGFR1 was unchanged and
βKlotho expression was increased by +30% (Fig. 3D). Consequently,
the expression of glucose transporter, GLUT1 and GLUT 4 wasenhanced in sc. WAT (+185%, +207%, respectively) and BAT
(+30%, +59%, respectively) and serum glucose levels were reduced
by 42% (Figs. 3E and F). Subsequently, uncoupling protein-1 (UCP-1)
expressionwhich is also induced in linewith a FGF21 effect [29] was in-
creased in BAT (Fig. 3G) and WAT (Fig. 3H). However, its expression in
WAT was very low compared to the BAT (Fig. 3G and H, right).
It has been previously shown, by separately feedingmicewith either
methionine- or choline-deﬁcient diet that WAT loss by MCD feeding is
due to the deﬁciency of methionine (and not choline) [8]. Additionally,
dietary methionine restriction has been shown to reduce adiposity and
increase energy expenditure both in humans and rodents [33–36]. The
effect is via the Cyclic AMP (cAMP) signalingwhich represents the prin-
cipal prolipolytic pathway in WAT and BAT, which is chieﬂy regulated
by the SNS [23,37]. Dietary methionine restriction produces a chronic
increase in SNS outﬂow to the adipose tissue producing a coordinated
set of changes inWAT and BATwhich limits fat deposition and increases
energy expenditure [34]. Increased UCP-1 levels in BAT (Fig. 3G) and
WAT (Fig. 3H) are also indicative of increase in SNS stimulation of
adipose tissue [23,34,35,37]. Collectively, these ﬁndings suggest that
MCD diet may induce WAT and BAT lipolysis (ATGL and HSL activity)
through enhanced FGF21 signaling in addition to increased SNS outﬂow
to the adipose depots.
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Next, we determined NEFA composition in serum and liver of MCD-
and chow-fed ob/ob mice by gas chromatographic/negative ion chemi-
cal ionization mass spectrometry (GC–NICI/MS). 18:2n6 (linoleic acid),
was themajor free FA species found to be signiﬁcantly elevated (+89%)
in serum of MCD-fed mice. While there was a modest decrease in fatty
acids – 18:0, 18:1n11 and 20:4n6 (Fig. 4A). GC–NICI/MS of NEFAs in
liver showed a marginal but signiﬁcant increase in the saturated fatty
acids – 14:0 (+17%), 16:0 (+28%), and 18:0 (+30%), (Fig. 3B). With
respect to the monounsaturated fatty acid (MUFA), only 16:1n7
was signiﬁcantly increased (+27%) in MCD-fed mice while there was
no signiﬁcant change in the levels of 18:1n9 and 18:1n11. While the
polyunsaturated fatty (PUFA) acid – 18:2n6 showed the maximal
increase (+195%) followed by 20:4n6 (+90%) in MCD-fed ob/ob
mice (Fig. 4B).
We next analyzedwhether the increased levels of these fatty acids in
liver were due to increased lipolytic ﬂux from the adipose tissue or dueto increase in DNL or elongation and desaturation of fatty acids in
the liver. Our analysis of mRNA expression revealed markedly re-
duced expression of genes involved in DNL and MUFA synthesis, in-
cluding sterol regulatory element-binding protein 1c (SREBP1c,
−55%), acetyl CoA carboxylase 1 (Acc1, −81%), fatty acid synthase
(FASN, −85%), stearoyl-CoA desaturase-1 (SCD1, −98%) and fatty
acid elongase 6 (ELOVL6, −76%) in MCD-fed ob/ob mice (Fig. 4C),
suggesting that the increased levels of FAs – 14:0, 16:0, 18:0 and
16;1n7 – were the contribution from WAT. Increased level of 18:2n6
in liver was the direct contribution from AT since it is an essential FA.
20:4n6 is also the elongation and desaturation product of 18:2n6 by
fatty acid elongase – ELOVL5 – and fatty acid desaturases – FADS2 and
FADS1. However, the expression of these genes was all down-regulated
in MCD-fed ob/ob mice by 48–82% (Fig. 4D), suggesting that increased
level of 20:4n6 was the contribution from WAT. Additionally, mRNA
level of lipoprotein lipase (LPL) was markedly elevated (+79%) while
its inhibitor, Apo-CIII was reduced (−50%) in MCD-fed ob/ob livers,
which may implicate an additional role for increased LPL-mediated FA
uptake by the liver (Fig. 4E).
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liver and TG hydrolase activity in liver
Since fatty acids are predominantly present/stored in the esteriﬁed
form, we therefore analyzed TFA (all FAs from triglyceride, cholesterol
ester or phospholipid pool) composition in serum and liver by GC–MS.
Serum analysis showed overall reduced TFA composition (Fig. 5A)
whereas, analysis of TFA composition in the liver showed an overall
increase of all PUFAs, while 18:0 was the only saturated FA elevated in
ob/obMCD-fed livers (Fig. 5B). In line, our analysis of mRNA expression
in liver revealed reduced expression of genes involved in fatty acid
oxidation, including peroxisome proliferator-activated receptor α
(PPARα, −51%), carnitine palmitoyltransferase 1α (CPT1α, −33%),
acyl-CoA oxidase (ACO, −57%), long-chain acyl Co-A dehydroge-
nase (LCAD, −27%) and very long-chain acyl Co-A dehydrogenase
(VLCAD,−23%) (Fig. 5C). Subsequently, liver TG content was increased
by 2-fold in MCD-fed ob/ob mice (Fig. 5D). In contrast to the increased
total lipase activity in WAT of MCD-fed ob/ob mice, in liver, total lipase
activity decreased by −18% (Fig. 5E, white bar). ATGL activity was
lowered by −19% in MCD-fed ob/ob mice, while no change in HSL
activity was observed (Fig. 5E, black and gray bars respectively).
In line, western blot analysis showed signiﬁcant decrease in protein
expression of ATGL whereas HSL expression remained unchanged
(Fig. 5F). Collectively, these ﬁndings suggest that in addition to
reduced VLDL synthesis and secretion from the liver (data not
shown) [38] hepatic fat accumulation in MCD-fed ob/ob mice may
result from the combined effects of ﬂux of free FAs from adipose
tissue depots to the liver, reduced TG hydrolase activity and FA oxidation
in the liver.3.6. Effect of MCD diet on liver injury and NAFLD activity score (NAS)
Following massive fatty acid ﬂux from adipose tissue, MCD feeding
resulted in pronounced liver injury as reﬂected by increased serum
levels of bilirubin, bile acids (BAs), alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) (Fig. 6A, left) together with
hepatic inﬂammation reﬂected by increased mRNA expression of
tumor-necrosis factor-alpha (TNFα), inducible nitric oxide synthase
(iNOS), monocyte chemotactic protein-1 (MCP-1), and interleukin
1beta (IL1β) (Fig. 6A, right). In addition, NAS scoring, performed by
pathophysiological examination revealed signiﬁcantly higher scores in
MCD-fed group as compared to the controls (Fig. 6B). In line, histological
scores for inﬂammation (Fig. 6C) and steatosis (Fig. 6D) were also high.
MCD-fed group showed microvesicular in addition to macrovesicular
steatosis (Fig. 6D, left). Ballooning was not clearly detected in this study.
Fibrosis was also not detected since leptin deﬁcient ob/ob mice are
resistant to ﬁbrosis [39].3.7. MCD feeding attenuates inﬂammatory markers in BAT but not WAT
mRNA expression analysis fromWAT did not show any difference in
inﬂammatory markers between the two groups (Fig. 7A, left). To deter-
mine whether these changes of inﬂammatory markers were due to
alteration in gene expression or to a change in macrophage number,
we performed IHC using an antibody that recognizes the macrophage
antigen F4/80. Consistent with the gene expression studies, macro-
phage number in gonadal adipose tissue remained unchanged in both
groups (Fig. 7A, middle and right).
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966 P. Jha et al. / Biochimica et Biophysica Acta 1842 (2014) 959–970In contrast toWAT, BAT showed even reduced expression of inﬂam-
matory markers in MCD-fed ob/ob mice (Fig. 7B, left). In line, the
macrophage number (F4/80) decreased by −63% in MCD-fed ob/ob
mice (Fig. 7B, middle and right). Our analysis of mRNA expression in
BAT revealedmarkedly reduced levels ofWAT enriched genes including
dermatopontin (DPT, −43%), homeobox protein C9 (Hoxc9, −65%)
and transcription factor 21 (Tcf21,−67%) in MCD-fed mice (Fig. 7C).
Furthermore, expression of genes involved in energy expenditure,
thermogenesis, mitochondrial and peroxisomal FA oxidation, such as
UCP-1 (Fig. 3G), CIDEA, ATP5B, COXIV, CPT1β, PPARα and PHYH were
all increased by 35–100% in BAT of MCD-fed ob/ob mice (Fig. 7D).
Together, these data in addition to the increased lipase activity in BAT
(Fig. 2E) suggest that MCD diet reduces adiposity in BAT and enhances
its activity and oxidative capacitywhichmay be responsible for reduced
inﬂammation in BAT.
4. Discussion
In the present study, we have examined the speciﬁc contribution of
adipose tissue in causing hepatic steatosis and inﬂammation as key
steps in the progression of NASH. Our data provides compelling evi-
dence to show that increased ATGL and HSL activity in adipose tissue
causes changes in FA homeostasis in serum and liver of MCD-fed miceand consequently leads to hepatic steatosis and lipotoxicity. Enhanced
FGF21 signaling and its inﬂuence on adipose depots may partly be re-
sponsible for increased lipase activity in adipose depots. We also show
that MCD diet augments BAT activity and reduces its inﬂammatory
markers in ob/ob mice.
MCD diet is a widely used dietary model of NASH in mice which re-
sults in liver injury resembling human NAFLD/NASH and is increasingly
used to obtain insights into the pathogenesis of NASH although several
shortcomings such as weight loss, lack of insulin resistance and obesity
in this model have to be acknowledged [3–5,27]. Therefore, we com-
bined MCD diet with ob/ob mice as an established model of NAFLD.
The contribution of WAT in the pathogenesis of NASH in this model
has not been studied, despite its signiﬁcant role in NAFLD patients
[13]. Earlier studies have shown weight and WAT loss on MCD feeding
[27,40], but the underlying mechanisms have remained unclear. In
humans, increased peripheral FA ﬂux has been shown to contribute
~59% to the hepatic TG content as opposed to ~26% by DNL and ~15%
from the diet in NAFLD patients [13]. Our study now demonstrates
that when applied to ob/ob mice on MCD diet as a murine model of
NASH, increased ATGL and HSL activities resulted in massive loss of all
WAT depots, thus increasing the ﬂux of FAs from adipose tissue to
liver. As such, the MCD model mimics the hepatic stress resulting
from FA ﬂux to the liver, in addition to its potential direct impact on
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967P. Jha et al. / Biochimica et Biophysica Acta 1842 (2014) 959–970liver causing oxidative stress as a result of micronutrient deﬁciency
[8,9]. Moreover, the WAT loss observed under MCD feeding may also
reﬂect part of the pathomechanisms resulting in steatosis and NASH
under severe calorie restriction and massive weight loss after bariatric
surgery [18,19,41,42] in addition to WAT mobilization seen in insulin-
resistance states.
We have earlier shown that short-term MCD feeding or cancer-
induced cachexia increases lipase activity and causes WAT loss in WT
and HSL-KO mice and that ATGL-KO mice are partially protected from
WAT loss [3,43]. Based on these ﬁndings, together with our current
observations, it is quite conceivable that ATGL may be the rate limiting
metabolic lipase responsible for increased FA ﬂux from adipose tissue
in human NAFLD/metabolic syndrome patients also, as it is for patients
suffering from cancer-induced cachexia [43]. Notably, various WAT
depots behaved differently in terms of lipolytic activity mediated fat
loss, with visceral WAT showing the highest rate of mobilization and
subcutaneous the least. These observations inmice are in linewith lipol-
ysis from WAT as a major source of FA in humans where visceral WAT
has a higher rate of mobilization compared to subcutaneous WAT [44].
Furthermore, venous blood from visceral fat is directly drained to the
liver through the portal vein. Therefore visceral fat is metabolically
more active and is the major contributing source in the overﬂow ofFAs to the liver [13]. Notably, expansion of visceral but not subcutane-
ous fat depots has been linked to insulin resistance and NAFLD [45].
It has been previously shown that reduction in body weight after
MCD feeding is a characteristic of methionine deﬁciency [8] and was
not associated with the biochemical effect of fasting [46]. Moreover,
WT mice on MCD diet consumed similar amount of food as their con-
trols [3,40,46,47]. Thus it would be incorrect to conclude that adipose
tissue loss is related entirely to reduced food intake. It has been
shown that FGF21 acts via activation of BAT and browning ofWAT, lead-
ing to increased glucose uptake and energy metabolism [29]. While our
results are in line in these effects of FGF21 in adipose tissue, a clear indi-
cation of browningofWATwasnot observed at the level of gene expres-
sion andWATmorphology (data not shown). FGF21 gene expression in
WAT and BAT per se was not increased (data not shown), but the in-
crease in expression of its receptors in these depots suggests that the
FGF21-mediated effect in adipose depots may be due to the enhanced
systemic levels of FGF21. Based on these ﬁndings, together with the
previous reports of FGF21 action on adipose tissue [29–32], it is quite
conceivable that part of the mechanism for increased lipase activity
in adipose tissue is mediated via FGF21. Alternatively, increased
SNS activation-βadrenergic stimulation-mediated increase in lipase ac-
tivity due to dietary methionine restriction may also be involved
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968 P. Jha et al. / Biochimica et Biophysica Acta 1842 (2014) 959–970[23,34,35,37]. Similarly, deprivation of another essential amino acid –
leucine, decreased fat mass by stimulation of lipolysis in WAT and
upregulation of UCP-1 in BAT [48]. Our present data on serum FGF21
levels is also in line with the earlier study in humans which showed
that hepatic FGF21 mRNA expression was signiﬁcantly elevated in
NAFLD patients and it correlated with a substantial increase in serum
FGF21 in these patients [49].
Our data demonstrates the importance of separately analyzing
different FA pools, i.e total FA (free and esteriﬁed) and free FA/NEFA.
Analysis of NEFA in serum revealed that 18:2n6 was preferentially
released from adipose tissue into the serum. This indicates that
esteriﬁed-18:2n6 could be one of the preferred substrates of ATGL. In-
deed it has been shown earlier that ATGL preferentially hydrolyses
long-chain FA esters in vivo (upon 8 h fasting) [50]. Increased level of
non-esteriﬁed 18:2n6 (+195%) in liver (Fig. 4B) was the direct contri-
bution from AT (Fig. 4A) which needs to be esteriﬁed into TG's and
again rehydrolysed by ATGL before they can become active signaling li-
gands for PPARα [51]. Subsequently, esteriﬁed 18:2n6 was also
increased in the liver by 193% (Fig. 5B) which implies that 18:2n6 was
unavailable for PPARα activation because it was not hydrolysed by
ATGL due to reduced ATGL activity (Fig. 5E). Therefore, despite in-
creased levels of important PPARα ligands – 18:2n6 and 20:4n6 – in
the liver, MCD-fed ob/ob mice showed attenuated PPARα signaling
and enhanced inﬂammation. The massive increase of overall TFA com-
position in the liver of MCD-fed ob/obmice reﬂects the combined effect
of increased fatty acid ﬂux from adipose tissue, decreased oxidation
of fatty acids and reduced TG hydrolase activity in the liver. Excess
FA accumulation may further sensitize the liver for injury andinﬂammation. Further, the lack of FA hydrolysis and oxidation, limits
the ligand availability for PPARα signaling as well as other cellular
signaling processes dependent on lipolytic products and their inter-
mediates [22]. PPARα insufﬁciency further leads to aggravation of
NASH [52] which is accentuated in ATGL-KO mice due to the lack of
ATGL-mediated generation of FAs as ligands for PPARα [3]. In contrast
to the NEFA proﬁle in serum and liver, the TFA proﬁle in serum showed
an overall decreased composition of FA specieswhichmay be attributed
to the reduced lipoprotein synthesis and excretion from the liver [7].
A previous human study showed that impaired BAT activity or the
absence of it in adult life is associated with an increased risk of fatty
liver [53], similar to associations found in obesity and diabetes mellitus
patients [54]. While reduced BATmass in MCD-fed ob/ob mice is in line
with the human data, increased BAT activity contrasts this preliminary
human study. Further studies are required to elucidate these observa-
tions in both humans and rodents.
It would be ideal to conduct pair-feeding experiments to match
weight loss in control andMCD-fed ob/obmice, although such is the se-
verity of weight loss in MCD-fed mice that this would be technically
very challenging. Our study was focused on a relatively late stage of
MCD feeding and therefore it is plausible that in the early stages there
may bemore contribution of DNL to hepatic steatosis.Whether blocking
peripheral lipolysis could limit hepatic steatosis and further progression
to NASH remains to be determined. However, since ATmay also provide
ligands for PPARα activation in the liver, blocking peripheral lipolysis
may also exaggerate the inﬂammatory response in progression to
NASH. We have previously shown that despite partial protection from
WAT loss (40–50%), genetic ablation of ATGL leads to pronounced
969P. Jha et al. / Biochimica et Biophysica Acta 1842 (2014) 959–970hepatosteatosis upon MCD feeding. This ﬁnding strongly suggests the
role of other yet unknown lipase(s) which need to be further investigat-
ed [3]. Importantly, our ﬁndings from the present and previous study
imply that the role of ATGL in the liver is imperative for TG hydrolysis
because the bottleneck is the reduced ATGL activity in the liver, follow-
ed by reduced oxidation of fatty acids which causes hepatosteatosis.
This effect is further accentuated in ATGL-KO mice [3].
In conclusion, our data support a key role for increased ATGL and
HSL activity in adipose tissue, leading to increased FA delivery and TG
production in the liver in conjunction with a compromised capacity of
the liver to compensate with increased hepatic lipolysis, FA oxidation
and TG export in this model of NASH. Our ﬁndings demonstrate an
important conceptual advance in understanding the mechanisms by
which MCD diet causes hepatic steatosis and inﬂammation by mimick-
ing the shift of FA/TG partitioning fromWAT to the liver to mimic this
important aspect in the pathogenesis of NASH.
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